Clinical Trials Logo

Filter by:
NCT ID: NCT03452540 Terminated - Clinical trials for Severe Acute Decompensated Alcoholic Hepatitis

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

Start date: November 28, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in adult patients with acute decompensated alcoholic hepatitis

NCT ID: NCT03452527 Terminated - Clinical trials for Choroidal Neovascularization

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

DECO
Start date: March 26, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.

NCT ID: NCT03452137 Terminated - Clinical trials for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Start date: April 3, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN)

NCT ID: NCT03451773 Terminated - Pancreatic Cancer Clinical Trials

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Start date: May 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Background: Pancreas cancer ranks 4th in all cancer-related deaths in the United States (U.S.) Gemcitabine is a standard treatment for it. M7824 (MSB0011359C) blocks a pathway that prevents the immune system from effectively fighting cancer. The two drugs together might help people with pancreas cancer. Objective: To test if giving M7824 together with gemcitabine is safe and causes tumors to shrink. Eligibility: People ages 18 and older with pancreatic cancer already treated with standard therapies Design: Participants will be screened with: Medical history Physical exam Scans in a machine that takes pictures of the body Blood, urine, and heart tests Some participants may have a tumor sample removed. Participants will get M7824 by intravenous (IV) once every 2 weeks. They will continue until their disease gets worse or they have unacceptable side effects. After the first dose, participants will also get gemcitabine by IV once weekly for 7 weeks. Then they will get it as follows for up to 6 months: Skip 1 week, get the drug once a week for 3 weeks, skip 1 week. Before treatment on the first day of each cycle, participants will repeat screening tests. They will also have: Optional tumor biopsies before and after 3 cycles of therapy Questions about their well-being and function Genetic testing of tissue and blood samples Participants will have a follow-up visit 4-5 weeks after they stop therapy. This includes a physical exam, blood and urine tests, and maybe a scan. If their disease does not get worse, they will be invited for scans every 12 weeks.

NCT ID: NCT03451500 Terminated - Clinical trials for Age Related Macular Degeneration

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Neovascular AMD, and measure the effects on visual acuity and retinal abnormalities due to "wet" (neovascular) AMD. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Dry AMD and Geographic Atrophy, and measure the effects on visual acuity, area of geographic atrophy and other retinal abnormalities due to "dry" AMD.

NCT ID: NCT03451474 Terminated - Clinical trials for Spinal Cord Injuries

Restoring Hand Function Utilizing Nerve Transfers in Persons With Cervical Spinal Cord Injuries

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the safety and efficacy of nerve transfer surgery for restoring hand function as a therapy for patients with cervical spinal cord injury.

NCT ID: NCT03451253 Terminated - Clinical trials for Inflammatory Bowel Diseases

Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

Start date: April 12, 2018
Phase: N/A
Study type: Interventional

This pilot study will examine the benefit of this amino acid based hydration solution in patients with IBD who have undergone a total colectomy and have either ileostomies or jpouches. Findings from this study and possible future studies could have broad implications for patients with malabsorption resulting from many underlying conditions, including IBD.

NCT ID: NCT03451123 Terminated - Clinical trials for Pediatric Brain Tumors

FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors

Start date: April 23, 2018
Phase: Early Phase 1
Study type: Interventional

The primary objectives of this study are: 1. Determine the percentage of patients whose surgical plan would change with FET-PET/MRI compared to MRI alone. 2. Determine the percentage of patients who have residual tumor after surgery detected with FET-PET/MRI. A secondary objective of this study is: 1) Perform preliminary correlations between the pre- and post-surgical metabolic tumor volumes measured with FET-PET/MRI to progression free survival.

NCT ID: NCT03451006 Terminated - Aging Clinical Trials

Effect of Metformin on Frailty in 12 Subjects

Start date: May 24, 2018
Phase: Phase 2
Study type: Interventional

This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.

NCT ID: NCT03450707 Terminated - Cardiac Arrest Clinical Trials

Thiamine as a Metabolic Resuscitator After Cardiac Arrest

THACA
Start date: May 6, 2018
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on lactate, cellular oxygen consumption, global oxygen consumption and biomarkers of neurologic injury after out-of-hospital cardiac arrest (OHCA). .